Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) Short Interest Up 3,004.8% in December

Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) was the target of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 130,400 shares, an increase of 3,004.8% from the December 15th total of 4,200 shares. Currently, 1.4% of the shares of the stock are short sold. Based on an average trading volume of 999,800 shares, the days-to-cover ratio is presently 0.1 days.

A number of analysts have issued reports on ARDS shares. Northland Securities reduced their price objective on Aridis Pharmaceuticals from $22.00 to $10.00 and set an “outperform” rating on the stock in a research note on Thursday, November 11th. Zacks Investment Research raised Aridis Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday.

Shares of Aridis Pharmaceuticals stock opened at $1.54 on Friday. The stock has a market cap of $21.64 million, a price-to-earnings ratio of -0.41 and a beta of 0.20. The stock has a 50 day moving average price of $2.29 and a 200-day moving average price of $3.69. Aridis Pharmaceuticals has a one year low of $1.37 and a one year high of $8.47.

Aridis Pharmaceuticals (NASDAQ:ARDS) last announced its earnings results on Wednesday, November 10th. The company reported ($1.94) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.51) by ($1.43). The firm had revenue of $0.52 million during the quarter. Equities analysts expect that Aridis Pharmaceuticals will post -3.84 EPS for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of ARDS. Wealth Architects LLC purchased a new position in Aridis Pharmaceuticals during the 3rd quarter valued at $52,000. Geode Capital Management LLC purchased a new position in Aridis Pharmaceuticals during the 3rd quarter valued at $132,000. BlackRock Inc. boosted its holdings in Aridis Pharmaceuticals by 33.6% during the 3rd quarter. BlackRock Inc. now owns 42,227 shares of the company’s stock valued at $156,000 after acquiring an additional 10,614 shares during the period. Millennium Management LLC purchased a new position in Aridis Pharmaceuticals during the 3rd quarter valued at $274,000. Finally, Vanguard Group Inc. boosted its holdings in Aridis Pharmaceuticals by 6.9% during the 2nd quarter. Vanguard Group Inc. now owns 159,946 shares of the company’s stock valued at $1,184,000 after acquiring an additional 10,288 shares during the period. Institutional investors own 14.17% of the company’s stock.

Aridis Pharmaceuticals Company Profile

Aridis Pharmaceuticals, Inc engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-101, AR-501, AR-712, AR-701, AR-401, AR-105 and AR-201. The company was founded by Eric J.

Read More: Why is momentum important to successful trading?

Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.